Sponsor Pipeline

RTOG Foundation, Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
3
Active Trials
0
Recruiting
2
Disease Areas
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-14 NCT06955169
Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment…		 overall status: Suspended → Active, Not Recruiting
2026-08-14 NCT06955169
Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment…		 Enrollment reduced: 153 -> 4 participants
Active Trials by Phase
Phase 2
3
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT03809000 A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer… Prostate Cancer Active, Not Recruiting
NCT03546582 SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head… Head and Neck Squamous Cell Carcinoma (HNSCC) Active, Not Recruiting
NCT06955169 Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment… Intracranial Meningioma Active, Not Recruiting
Disease Areas
Head & Neck Cancer (1) Prostate Cancer (1)
Get alerts when RTOG Foundation, Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free